Search results for "Radiothérapie"

showing 7 items of 7 documents

Evaluation of proton MR spectroscopy at 3 Tesla without endorectal coil in patients with a localized prostate cancer treated with exclusive radiother…

2011

Prostate cancer is the most frequent tumour affecting the male population. When the prostate is not removed and is treated with radiation therapy, PSA slowly decreases over time to reach its nadir, even sometimes 18 to 24 months after the completion of radiation therapy without combined androgen suppression therapy. When combined with hormones, PSA falls abruptely with no possibility to perceive the impact of either hormones or radiation effects on PSA.The optimal value of PSA that should be reached after radiation therapy (nadir) and time to this nadir are still unclear.Even when a satisfactory value of the PSA nadir is reached, on-going variations of the PSA and its “bounce” effects, whic…

BiomarqueursRéponse thérapeutique[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyProstate cancerTherapeutic responseRadiotherapySpectroscopieCancer de la prostateIRM fonctionnelle[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyBiomarkersSpectroscopy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFunctional MRIRadiothérapie
researchProduct

Association de radiothérapie externe et de curiethérapie pour les cancers de la prostate

2017

International audience; Brachytherapy as sole treatment is standard of care for D’Amico classification low-risk prostate cancer. For intermediate and high-risk patients, brachytherapy can be associated to external beam radiation therapy to better take into account the risk of extracapsular effraction and/or seminal vesicle involvement. Three randomized studies have shown that this association increases freedom from relapse survival compared to exclusive external beam radiation therapy. This benefit is not shown for overall survival. The addition of a hormonal therapy to this association is most likely mandatory for high-risk patients, and needs to be confirmed for intermediate risk patients…

Oncologymedicine.medical_specialtyStandard of caremedicine.medical_treatmentBrachytherapyBrachytherapy[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesProstate cancer0302 clinical medicineProstateInternal medicineMedicineRadiology Nuclear Medicine and imagingBoostRadiothérapieCancerGynecologyRadiotherapybusiness.industryGenitourinary systemProstateCancermedicine.disease3. Good healthRadiation therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCuriethérapieHormonal therapybusiness
researchProduct

Titanate nanotubes as versatile nanovectors : radiosensitizers for the treatment of prostate cancer and nuclear imaging probes

2017

Currently, the systemic injections of drugs reach very weakly tumor sites and large doses are thus administered causing adverse side effects. The new implementations of nanoparticles in the medical field offer new strategies to vectorize an active substance in diseased cells. This work is focused on the prostate cancer, which is the second most frequently diagnosed cancer and the fifth leading cause of cancer death in men worldwide.Titanate nanotubes (TiONts) are synthetized by a hydrothermal process and have average dimensions of about 170 nm in length, 10 nm in outer diameter and also have an internal cavity of 4 nm in diameter. Their needle-shaped morphology allows them to be internalize…

Prostate cancerRadiotherapySpect[CHIM.THER] Chemical Sciences/Medicinal ChemistryFonctionnalisation[ CHIM.THER ] Chemical Sciences/Medicinal Chemistry[CHIM.THER]Chemical Sciences/Medicinal ChemistryCancer de la prostateTitanate nanotubesDocétaxel[PHYS.PHYS.PHYS-CHEM-PH] Physics [physics]/Physics [physics]/Chemical Physics [physics.chem-ph][ PHYS.PHYS.PHYS-CHEM-PH ] Physics [physics]/Physics [physics]/Chemical Physics [physics.chem-ph][CHIM.RADIO] Chemical Sciences/Radiochemistry[PHYS.PHYS.PHYS-CHEM-PH]Physics [physics]/Physics [physics]/Chemical Physics [physics.chem-ph]Nanotubes de titanateFunctionalization[CHIM.RADIO]Chemical Sciences/Radiochemistry[ CHIM.RADIO ] Chemical Sciences/RadiochemistryRadiothérapie
researchProduct

Ne sous-estimons pas le risque à long terme de second cancer pulmonaire après exérèse chirurgicale d'un cancer du poumon non à petites cellules

2019

Etat de la question Plusieurs etudes ont montre que les survivants d’un cancer du poumon sont a haut risque de developper un second cancer broncho-pulmonaire (SCBP). L’evaluation du risque de SPBC au cours du temps a d’importante repercussion sur la strategie de surveillance post-chirurgicale des cancers du poumon non a petites cellules (CPNPC). L’objectif principal de cette etude etait de mesurer le risque de SCP sur le long terme en tenant compte du risque competitif de deces. Materiel et methodes Le risque cumule de SCBP a ete estime a l’aide de l’incidence cumulee chez des patients operes en resection complete d’un CPNPC de stade I a III diagnostiques entre 2002 et 2015 et recenses par …

Second cancer broncho-pulmonaireEpidemiologyPublic Health Environmental and Occupational HealthRadiothérapie adjuvantesuivi[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieEnquête en populationCancer du poumon non à petites-cellulesComputingMilieux_MISCELLANEOUSRisque compétitifs3. Good health
researchProduct

Rapport annuel 2006-2007 de l'Observatoire national de la démographie des professions de santé.

2008

Ce troisième rapport de l'Observatoire national de la démographie des professions de santé comporte une synthèse générale assortie de préconisations et de quatre tomes thématiques : la médecine générale (tome 1), les internes en médecine (tome 2), la profession de chirurgien dentiste et les métiers de la périnatalité (tome 3), les métiers de la cancérologie (tome 4).

Spécialité médicale[SHS.SOCIO] Humanities and Social Sciences/SociologyEvolutionOffre soinsPédiatrieDémographie médicalePérinatalogieManipulateur électroradiologieNéonatologieInterneBloc opératoireDonnée statistiquePratique professionnelle[SHS]Humanities and Social SciencesSage femmeMédecine généraleProfession santéEquipement litFormation professionnelleInfirmier bloc opératoireOrganisation travailAnesthésieComputingMilieux_MISCELLANEOUSRadiothérapieChirurgien[SHS.SOCIO]Humanities and Social Sciences/SociologyChirurgien dentisteRégionHistoire professionnelleCancérologieGynécologie obstétrique[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie[SHS] Humanities and Social SciencesFranceMode exercice professionnelPuéricultriceQualitéEffectif
researchProduct

Hypofractionnated radiotherapy for elderly patients with prostate cancer

2018

Radiation therapy technique and schedules could be adapted to patient's age because of a natural history of prostate cancer perceived as different, taking into account the comorbidities of patients but also a particular tolerance of elderly subjects. Thus, in localized prostate cancer, evaluation of associated diseases is essential before considering a treatment that will be of interest only if the life expectancy is greater than 10 years. When a curative approach is decided, radiotherapy holds a place of choice. Due to the recent results of randomized studies evaluating moderate hypofractionnated radiotherapy, showing a carcinological equivalence compared to a standard fractionation, this …

[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingFractionation SchedulesNon-InferiorityProstate[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRadiothérapie hypofractionnée Sujet âgé Cancer de la prostate OncogériatrieRadical ProstatectomyOlder MenGeriatric assessment[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicineIntensity-Modulated RadiotherapyQuality-Of-LifeElderly patientsExpectancy[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging[SDV.CAN] Life Sciences [q-bio]/CancerBeam Radiation-TherapyAndrogen-Deprivation TherapyHypofractionnated radiotherapyPhase-3 Chhip Trial
researchProduct

Etude du rôle d'un donneur de monoxyde d'azote (Glycéryl Trinitrate) dans la mort cellulaire immunogène induite par des chimiothérapies (FOX) et/ou r…

2017

Le cancer colorectal se situe au 3ème rang mondial des cancers les plus fréquents derrière les cancers du sein et du poumon. Dans le cas de cancer colorectal métastatique, la première ligne thérapeutique repose sur l’utilisation d’une association de chimiothérapies : le FOLFOX (acide FOLinique, 5-Fluorouracile et OXaliplatine). Malgré une forte efficacité anti-tumorale de cette combinaison, de nombreuses rechutent apparaissent nécessitant l’utilisation de nouvelles stratégies basées sur l’association du FOLFOX à d’autres agents anti-cancéreux ou stimulant le système immunitaire. Cette étude a eu comme objectif d’étudier l’effet anti-tumoral del’association du FOX (5-Fluorouracile et OXalipl…

[SDV] Life Sciences [q-bio]Mort cellulaire immunogène[ SDV ] Life Sciences [q-bio]Colon[SDV]Life Sciences [q-bio]Monoxyde d'azoteChimiothérapiesCalréticulineRadiothérapieCancer
researchProduct